TY - CONF
T1 - Impact of Partial Nephrectomy and Percutaneous Cryoablation on Health-related Quality of Life Two Years After Treatment – A prospective Comparative Cohort Study
AU - Junker, Theresa
AU - Aarup Duus, Louise
AU - Norgaard, Birgitte
AU - Brandt Rasmussen, Benjamin Schnack
AU - Lund, Lars
AU - Azawi, Nessn H
AU - Graumann, Ole
N1 - Danske Kræftforskningsdage - Danish Cancer Research Days 2023 ; Conference date: 31-08-2023 Through 01-09-2023
PY - 2023/8/31
Y1 - 2023/8/31
N2 - Presenting author: Theresa Junker, RN, PhD Presenting author's affiliation Research and Innovation Unit of Radiology, Odense University Hospital All authors and affiliation, including presenting author Junker, T. (1,2) Duus, L.A. (1) Nørgaard, B. (3) Azawi, N. (4,5) Rasmussen, B.S.B. (1,2) Lund, L. (6,2) Graumann, O. (1,2) 1: Research and Innovation Unit of Radiology, Odense University Hospital, 2: Department of Clinical Research, University of Southern Denmark 3: Department of Public Health, University of Southern Denmark 4: Department of Urology, Zealand University Hospital Roskilde 5: Department of Clinical Medicine, University of Copenhagen 6: Department of Urology, Odense University HospitalIntroductionPartial nephrectomy (PN) is the gold standard for treating renal cell carcinoma (RCC) stage cT1.However, alternative minimally invasive treatments, such as percutaneous cryoablation (PCA),have been proposed to minimize the adverse effects on patient’s health-related quality of life(HRQoL). We aimed to evaluate and compare the HRQoL of patients treated with PN or PCA forRCC stage cT1 two years after treatment.Materials & MethodsPatients treated with PN or PCA for RCC stage cT1 between 2019 and 2021 at two universityhospitals in Denmark were offered inclusion. Exclusion criteria: insufficient understanding of theDanish language, cognitive deterioration, conversion to nephrectomy, or salvage procedures. TheEORCT QLQ C30 questionnaire was distributed before treatment and at one- and two-years posttreatment. A linear mixed-effect model was used to analyze changes from baseline to follow-upbetween the groups.ResultsWe included 168 patients (PN: 79; PCA: 89). The response rate was 100% at baseline and 88% and74% after one and two years, respectively. Patients receiving PCA were significantly older (median69.0 vs. 62.1 years), had a significantly higher score on the Charlson Comorbidity Index (3 vs. 2),and were treated for significantly smaller tumors (3.06 vs. 3.75 cm) compared to PN. Patientstreated with PCA had lower baseline scores on physical (p < 0.001), role (p = 0.004), and socialfunctioning (p=0.044) compared to PN. A significant difference from baseline to one-year followup wasfound for emotional functioning (p=0.006), favoring PCA over PN as the only HRQoLscale. No significant changes from baseline to the two-year follow-up were found for any HRQoLscales.ConclusionsWe found significant differences between baseline HRQoL between patients treated with PCA andPN. However, no significant differences between the treatment groups were observed in anyHRQoL scales from baseline to two-year follow-up
AB - Presenting author: Theresa Junker, RN, PhD Presenting author's affiliation Research and Innovation Unit of Radiology, Odense University Hospital All authors and affiliation, including presenting author Junker, T. (1,2) Duus, L.A. (1) Nørgaard, B. (3) Azawi, N. (4,5) Rasmussen, B.S.B. (1,2) Lund, L. (6,2) Graumann, O. (1,2) 1: Research and Innovation Unit of Radiology, Odense University Hospital, 2: Department of Clinical Research, University of Southern Denmark 3: Department of Public Health, University of Southern Denmark 4: Department of Urology, Zealand University Hospital Roskilde 5: Department of Clinical Medicine, University of Copenhagen 6: Department of Urology, Odense University HospitalIntroductionPartial nephrectomy (PN) is the gold standard for treating renal cell carcinoma (RCC) stage cT1.However, alternative minimally invasive treatments, such as percutaneous cryoablation (PCA),have been proposed to minimize the adverse effects on patient’s health-related quality of life(HRQoL). We aimed to evaluate and compare the HRQoL of patients treated with PN or PCA forRCC stage cT1 two years after treatment.Materials & MethodsPatients treated with PN or PCA for RCC stage cT1 between 2019 and 2021 at two universityhospitals in Denmark were offered inclusion. Exclusion criteria: insufficient understanding of theDanish language, cognitive deterioration, conversion to nephrectomy, or salvage procedures. TheEORCT QLQ C30 questionnaire was distributed before treatment and at one- and two-years posttreatment. A linear mixed-effect model was used to analyze changes from baseline to follow-upbetween the groups.ResultsWe included 168 patients (PN: 79; PCA: 89). The response rate was 100% at baseline and 88% and74% after one and two years, respectively. Patients receiving PCA were significantly older (median69.0 vs. 62.1 years), had a significantly higher score on the Charlson Comorbidity Index (3 vs. 2),and were treated for significantly smaller tumors (3.06 vs. 3.75 cm) compared to PN. Patientstreated with PCA had lower baseline scores on physical (p < 0.001), role (p = 0.004), and socialfunctioning (p=0.044) compared to PN. A significant difference from baseline to one-year followup wasfound for emotional functioning (p=0.006), favoring PCA over PN as the only HRQoLscale. No significant changes from baseline to the two-year follow-up were found for any HRQoLscales.ConclusionsWe found significant differences between baseline HRQoL between patients treated with PCA andPN. However, no significant differences between the treatment groups were observed in anyHRQoL scales from baseline to two-year follow-up
M3 - Paper
SP - 27
ER -